Novo Replaces CEO Jorgensen After Lilly Rivalry Hits Shares
Novo Nordisk A/S is replacing CEO Lars Fruergaard Jorgensen due to increased competition for its Wegovy obesity shots and a 53% decline in its share price over the past 12 months. The company's share price has sliced more than $300 billion off its market value, and it has faced setbacks in trials of new weight-loss drugs and growing competition from Eli Lilly & Co. Jorgensen will continue as CEO for a period to support a smooth transition to new leadership, and the search for a new leader has begun. Bloomberg Intelligence's Michael Shah reports. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
DDB Worldwide Named Cannes Lions 2025 Network of the Year for the Second Time in Two Years
Omnicom Network Achieves Record Number of Wins in 76-Year History Under Recently Appointed Global Leadership CANNES, France, June 20, 2025 /CNW/ -- DDB Worldwide, part of Omnicom, has once again claimed the prestigious title of Network of the Year at the 2025 Cannes Lions International Festival of Creativity. This marks the second time the network has secured the honor, following its historic first win in 2023. In a record-breaking year, DDB surpassed its 2023 award tally with a total of 112 Lions, further cementing its place at the forefront of the global creative industry. DDB's continued rise comes just one year into the leadership of Global CEO Alex Lubar and President & Global Chief Creative Officer, Chaka Sobhani. Since taking the reins, the duo has steered the network into a new era; one defined by tighter integration, emotionally-led creativity, and a sharpened focus on work that delivers both cultural impact and real business results. Chaka Sobhani commented: "I literally don't have the words. This means the absolute world to us. I couldn't be prouder of our DDB network and the passion, commitment, and love that has gone behind us getting here. A huge thank you also to our amazing clients for their trust and partnership - we wouldn't be here without you and I hope we've made you proud. Hopefully, this is the start of much more to come from DDB - and on a personal note, I can only say it's been the most incredible first year!" "2023 was a landmark year for DDB, but we saw it as the beginning," said Alex Lubar. "The momentum you're seeing now is the result of a global network aligned around a simple belief: creativity is the most powerful force in business. I'm incredibly proud of our exceptional teams and client partners on this collective effort." 2025 Cannes Lions highlights: Regional Network of the Year - Latin America Regional Network of the Year - Pacific Classic Track Agency of the Year - Africa Creative DDB Good Track Agency of the Year - Africa Creative DDB Experience Track Agency of the Year - DM9 Africa Creative DDB is the 1st ranked agency in Brazil, 2nd in Agency of the Year The first time DDB won four Grands Prix across different brands since 2016, including: Audio & Radio: "One Second Ads" (Budweiser, Africa Creative DDB) Music: "Tracking Bad Bunny" (Rimas Entertainment, DDB Latina Puerto Rico) Creative Data: "Efficient Way to Pay" (Consul, DM9) Sustainable Development Goals: "The Amazon Greenventory" (Natura, Africa Creative DDB) 20 total Gold Lions 37 total Silver Lions 51 total Bronze Lions 320 total shortlists First Gold Cannes Lion in Finland for Nordea, Parental Leave Mortgage First Grand Prix for DDB Latina Puerto Rico, and Puerto Rico's second in history First Gold for DDB Warsaw for McDonald's Winter Takes on Color in Brand Experience & Activation Most Lions and Grands Prix won by DDB Latina ever, with 78 trophies vs their previous record of 44 Most awarded network in Brand Experience & Activation with 20 trophies Most awards on behalf of McDonald's than any other agency network This creative surge has been powered by the DDB Global Creative Council, Bullseye, which is led by Global Chief Creative Operations Officer, Susie Walker, and continues to push boundaries across regions. This year, the program has been expanded to include rising creative talent, who have actively shaped DDB's award-winning creative work. DDB's rise has also been fueled by the growing influence of some of its most dynamic agencies, including DDB Paris, Africa Creative DDB, alma, DM9, and NORD DDB, whose bold, culturally resonant work continues to redefine the standard of global creative excellence. As creativity becomes an increasingly vital business differentiator, DDB's Cannes success proves its belief that emotional storytelling not only moves people, it moves markets. This year's winning campaigns have not only earned accolades but delivered measurable growth for clients across categories. ABOUT DDB WORLDWIDE DDB ( is The Emotional Advantage Agency. We believe when people feel, they act—and when they act, brands grow. That's the emotional advantage. We use it to deliver intimacy at scale, unlock brand growth, and craft ideas that move people, business, and culture forward. As one of the world's leading advertising and marketing networks, DDB blends creative excellence with strategic effectiveness to drive measurable results. With 140 offices in 60+ countries, we partner with iconic brands like MARS, McDonald's, Molson Coors, Volkswagen, Amazon, Unilever, JetBlue, Adidas, PlayStation, and the U.S. Army. Our impact is proven: we were named the #1 Most Awarded Agency Network in the 2024 Effie Global Best of the Best, Global Network of the Year by Cannes Lions (2023 and 2025), and D&AD Network of the Year for three consecutive years (2021–2023). We've also ranked as a Top 3 Global Network on WARC for 13 of the last 16 years. Founded in 1949, DDB is part of Omnicom (NYSE: OMC). Media ContactPress@ View original content to download multimedia: SOURCE DDB Worldwide View original content to download multimedia:
Yahoo
33 minutes ago
- Yahoo
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insights into the risk reduction for type 2 diabetes (T2D) and coronary artery disease (CAD) suggested by human genetics CAMBRIDGE, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of preclinical data supporting WVE-007, its GalNAc-siRNA designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. The data demonstrate the ability of Wave's long-acting GalNAc-siRNA to reduce INHBE mRNA and Activin E protein, induce weight loss mainly through reduction of fat mass, and reduce pro-inflammatory macrophage recruitment in a diet-induced obese (DIO) mouse model. The data were highlighted today in an oral presentation at the American Diabetes Association's 85th Annual Scientific Sessions, taking place June 20 to 23, in Chicago. 'These exciting preclinical data highlighted in today's presentation both recapitulate human genetics findings and continue to support the potential of WVE-007 to drive weight reduction by reducing Activin E to induce lipolysis – or fat breakdown, preferentially reducing visceral fat, and decreasing inflammation of adipose tissue – all without impacting lean muscle mass. These data suggest a highly differentiated therapeutic profile with lower visceral fat, less insulin resistance and less inflammation, supporting potential for risk reduction of T2D, CAD and other obesity-related co-morbidities,' said Erik Ingelsson, MD, PhD, Chief Scientific Officer. 'Silencing of INHBE is an entirely orthogonal mechanism from GLP-1s, which are centrally acting and impact the digestive system and central nervous system to decrease appetite. If these preclinical data translate in the clinic, WVE-007 has the potential to transform the obesity treatment paradigm by delivering healthy weight loss, preservation of muscle mass, and infrequent dosing of once or twice a year. We are evaluating WVE-007 in our ongoing INLIGHT clinical trial in adults living with overweight or obesity, and we are on track to deliver the first clinical data in the second half of this year.' Human genetics provides strong evidence for INHBE as a therapeutic target. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier cardiometabolic profile, including less abdominal fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease. These heterozygous carriers also exhibit favorable associations with liver traits, including reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), with no impact on liver fat. The oral presentation titled, 'siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile,' highlighted results from studies in DIO mice that evaluated monotherapy (INHBE-siRNA alone) as well as combination (INHBE siRNA and semaglutide), and maintenance (INHBE siRNA when semaglutide treatment is discontinued) treatment settings. Key results are as follows: A single dose of INHBE-siRNA led to robust target engagement, including reduction of INHBE mRNA and Activin E protein, a lipolysis suppressor that is upregulated in obesity. Liver INHBE mRNA was strongly correlated with serum Activin E levels following INHBE-siRNA treatment. A single dose of INHBE-siRNA led to weight loss on par with semaglutide. There was a decrease in diet-induced visceral adipose mass and shrinkage of adipocytes compared with PBS treatment, supporting the restoration of healthy adipose tissue with this mechanism of action. Muscle mass was preserved. Infiltration of activated macrophages in visceral adipose was significantly decreased by a single dose of INHBE-siRNA compared with PBS controls. INHBE-siRNA also significantly reduced proinflammatory M1 macrophage (CD11c positive) recruitment while sustaining levels of anti-inflammatory M2 macrophages in visceral fat, indicating an overall shift away from a pro-inflammatory state. When administered as an add-on to semaglutide, a single dose of INHBE-siRNA doubled the amount of weight loss, highlighting potential for combination treatment. Wave's INHBE siRNA curtailed rebound weight gain when semaglutide treatment was discontinued, highlighting its potential as an off-ramp and maintenance treatment following GLP-1 treatment. The full presentation can be accessed by visiting 'Scientific Presentations' on the Investors section of the Wave Life Sciences website: About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and Obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations for WVE-007 and the anticipated therapeutic benefits thereof; the anticipated timing of clinical data from our INLIGHT clinical trial of WVE-007; the novelty of our approach to silence INHBE mRNA in order to achieve healthy, sustainable weight loss and the potential for once- or twice-yearly dosing; the potential benefits of WVE-007 over existing obesity therapies; the potential of WVE-007's mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss; our understanding of our preclinical data for WVE-007 and our expectations of how such data will translate in humans; beliefs that Wave's portfolio of RNA medicines is differentiated, potentially best-in-class and potentially transformative; the broad potential of Wave's RNA medicines pipeline and oligonucleotide chemistry and any benefits that may arise as a result thereof. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled 'Risk Factors' in Wave's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827Investors:InvestorRelations@ Media:MediaRelations@ in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Forget chocolate! The world now envies Switzerland's zero interest rates
The world envies Swiss chocolate, army knives, and now . . . interest rates? Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos 3 tiny behaviors that make you the calmest person in the room Swiss National Bank, Switzerland's central bank, moved interest rates to zero this week, a reduction of 25 basis points, and a notable detraction from other central banks around the world, such as the Federal Reserve in the U.S. and the Bank of England in the U.K. In a statement, the Swiss National Bank said that the move was made in relation to declining inflation worries—and that it's expecting the economies to buckle under the volatility created, in part, due to the Trump administration's trade policies. 'With today's easing of monetary policy, the SNB is countering the lower inflationary pressure. The SNB will continue to monitor the situation closely and adjust its monetary policy if necessary, to ensure that inflation remains within the range consistent with price stability over the medium term,' the statement read. 'The global economic outlook for the coming quarters has deteriorated due to the increase in trade tensions. In its baseline scenario, the SNB anticipates that growth in the global economy will weaken over the coming quarters. Inflation in the U.S. is likely to rise over the coming quarters. In Europe, by contrast, a further decrease in inflationary pressure is to be expected.' Meanwhile, in the U.S., the Federal Reserve's latest meeting wrapped up this week with no change in interest rates, despite pressure from the White House and others to lower them. Fed Chair Jerome Powell and other Fed governors have been reluctant to do so, as inflation data still has not gotten close enough to its 2% target, and employment data has remained positive. Across the Atlantic, however, another European country, Norway, also cut rates this week. And some experts think that the Swiss could go even further, instituting negative interest rates at some point this year. 'There are risks that the SNB will go further in the future if inflationary pressures don't start to increase, and the lowest the policy rate could go is -0.75%, the rate it reached in the 2010s,' Swiss National Bank's Chairman Martin Schlegel told CNBC on Thursday. 'But what I can say is that going negative, we would not take this decision lightly.' This post originally appeared at to get the Fast Company newsletter:
